Botulinum toxin treatment of adductor spasmodic dysphonia: Longitudinal functional outcomes

Laryngoscope

Volumn 121, Issue 3, 2011, Pages 606-612

  Novakovic, Daniel ^a   Waters, Heather H ^b   D'Elia, Joanna B ^a   Blitzer, Andrew ^a  

^a New York Center for Voice and Swallowing Disorders   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

adductor; botulinum toxin; dystonia; quality of life; Spasmodic dysphonia; treatment outcomes

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADDUCTOR SPASMODIC DYSPHONIA; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DYSPHAGIA; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SPASMODIC DYSPHONIA; SPEECH ANALYSIS; SPEECH DISORDER; VOICE;

BOTULINUM TOXINS, TYPE A; COHORT STUDIES; DEGLUTITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSPHONIA; ELECTROMYOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LARYNGISMUS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; VOICE DISORDERS;

EID: 79951936061     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.21395     Document Type: Article

References (21)

1. Critchley M,. Spastic dysphonia ("inspiratory speech"). Brain 1939; 62: 96-103.
2. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE,. Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 1986; 96: 1300-1301.
3. Blitzer A, Brin MF, Stewart CF,. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998; 108: 1435-1441. (Pubitemid 28465236)
4. Humeau Y, Doussau F, Grant NJ, Poulain B,. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000; 82: 427-446. (Pubitemid 30391899)
5. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160-163. (Pubitemid 23282061)
6. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832-835.
7. Tisch SH, Brake HM, Law M, Cole IE, Darveniza P,. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients - an Australian experience. J Clin Neurosci 2003; 10: 434-438. (Pubitemid 36876651)
8. Hogikyan ND, Wodchis WP, Spak C, Kileny PR,. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001; 15: 576-586. (Pubitemid 33151976)
9. Rubin AD, Wodchis WP, Spak C, Kileny PR, Hogikyan ND,. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Arch Otolaryngol Head Neck Surg 2004; 130: 415-420. (Pubitemid 38456315)
10. Courey MS, Garrett CG, Billante CR, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol 2000; 109: 819-822.
11. Paniello RC, Barlow J, Serna JS,. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results. Laryngoscope 2008; 118: 564-568. (Pubitemid 351640641)
12. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Movement Disord 1987; 2: 237-254.
13. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E,. Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto Laryngol 1993; 113: 400-404. (Pubitemid 23124001)
14. Rosales RL, Arimura K, Takenaga S, Osame M,. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19: 488-496.
15. Giladi N,. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997; 152: 132-135. (Pubitemid 27509179)
16. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO,. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Nat Acad Sci USA 1999; 96: 3200-3205. (Pubitemid 29148868)
17. Sulica L, Blitzer A,. Botulinum treatment of spasmodic dysphonia and other laryngeal disorders. In:, Blitzer A, Brin MF, Ramig LO, eds. Neurological Disorders of the Larynx. 2nd ed. New York: Thieme; 2009: 196-203.
18. Dolly JO, Lisk G, Foran PG, et al. Insights into the extended duration of neuroparalysis by botulinum neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In:, Brin MF, Jankovic J, Hallet M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins; 2002: 91-102.
19. Holzer SE, Ludlow CL,. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Laryngoscope 1996; 106: 86-92. (Pubitemid 26015881)
20. Vasconcelos S, Birkent H, Sardesai MG, Merati AL, Hillel AD,. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. Laryngoscope 2009; 119: 2004-2007.
21. Blitzer A,. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otol Head Neck Surg 2005; 133: 836-838. (Pubitemid 41797231)